Search Results - "Kurtz, J. E."

Improved survival using specialized multidisciplinary board in sarcoma patients by Blay, J.-Y., Soibinet, P., Penel, N., Bompas, E., Duffaud, F., Stoeckle, E., Mir, O., Adam, J., Chevreau, C., Bonvalot, S., Rios, M., Kerbrat, P., Cupissol, D., Anract, P., Gouin, F., Kurtz, J. -E., Lebbe, C., Isambert, N., Bertucci, F., Toumonde, M., Thyss, A., Piperno-Neumann, S., Dubray-Longeras, P., Meeus, P., Ducimetière, F., Giraud, A., Coindre, J. -M., Ray-Coquard, I., Italiano, A., Le Cesne, A.

“…Sarcomas are rare but aggressive diseases. Specialized multidisciplinary management is not implemented for all patients in most countries. We investigated the…”
Get full text

Advanced chondrosarcomas: role of chemotherapy and survival by Italiano, A., Mir, O., Cioffi, A., Palmerini, E., Piperno-Neumann, S., Perrin, C., Chaigneau, L., Penel, N., Duffaud, F., Kurtz, J.E., Collard, O., Bertucci, F., Bompas, E., Le Cesne, A., Maki, R.G., Ray Coquard, I., Blay, J.Y.

“…There are limited data about the role of chemotherapy in patients with advanced chondrosarcomas. The medical charts of 180 patients with advanced…”
Get full text

Baseline nutritional status is prognostic factor after definitive radiochemotherapy for esophageal cancer by Clavier, J.-B., Antoni, D., Atlani, D., Ben Abdelghani, M., Schumacher, C., Dufour, P., Kurtz, J.-E., Noel, G.

“…Summary Identify prognostic factors for survival and patterns of treatment failure after definitive radiochemotherapy for esophageal cancer. Between 2003 and…”
Get full text

Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals by Barthélémy, P, Heitz, D, Mathelin, C, Polesi, H, Asmane, I, Litique, V, Rob, L, Bergerat, J.-P, Kurtz, J.-E

“…Abstract Purpose of the study Elderly breast cancer (EBC) patients are often denied adjuvant chemotherapy because of age. Breast cancer is among the most…”
Get full text

A propensity score–weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer by Bischoff, H., Bigot, C., Moinard-Butot, F., Pflumio, C., Fischbach, C., Kalish, M., Kurtz, J. E., Pierard, L., Demarchi, M., Karouby, D., Coliat, P., Pivot, X., Petit, T., Cox, D. G., Goepp, L., Bender, L., Trensz, P.

“…Purpose A 4-weekly schedule of pegylated liposomal doxorubicin (PLD) has been approved for the treatment of metastatic breast cancer (MBC). Phase II trials…”
Get full text

Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine by Husseini, F., Delord, J.-P., Fournel-Federico, C., Guitton, J., Erbs, P., Homerin, M., Halluard, C., Jemming, C., Orange, C., Limacher, J.-M., Kurtz, J.-E.

“…TG4023 is a modified vaccinia virus Ankara (MVA) containing the yeast-originated transgene FCU1, expressing cytosine deaminase and uracil…”
Get full text

Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO study group, AGO-Austria, ANZGOG, GINECO, SGCTG) by Pfisterer, J., Dean, A.P., Baumann, K., Rau, J., Harter, P., Joly, F., Sehouli, J., Canzler, U., Schmalfeldt, B., Shannon, C., Hein, A., Reimer, D.U., Hanker, L.C., Petit, T., Marmé, F., El-Balat, A., Glasspool, R., de Gregorio, N., Mahner, S., Kurtz, J.-E.

Get full text

Natural history of sarcomas and impact of reference centers in the nationwide NETSARC study on 35,784 patients (pts) from 2010 to 2017 by Blay, J.-Y., Toulmonde, M., Penel, N., Mir, O., Chevreau, C.M., Anract, P., Bompas, E., Rios, M., Firmin, N., Italiano, A., Piperno-Neumann, S., Kurtz, J.-E., Duffaud, F., Rosset, P., Bertucci, F., Perrin, C., Chemin, C., Ducimetiere, F., Gouin, F., Le Cesne, A.

Get full text

Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE by Thariat, J., Schouman, T., Brouchet, A., Sarini, J., Miller, R.C., Reychler, H., Ray-Coquard, I., Italiano, A., Verite, C., Sohawon, S., Bompas, E., Dassonville, O., Salas, S., Aldabbagh, K., Maingon, P., de La MotteRouge, T., Kurtz, J.E., Usseglio, J., Kerbrat, P., Raoul, G., Lotz, J.P., Bar-Sela, G., Brugières, L., Chaigneau, L., Saada, E., Odin, G., Marcy, P.Y., Thyss, A., Julieron, M.

“…Mandibular osteosarcomas (MOS) mostly affect young adults. Their treatment is extrapolated from that of extragnathic osteosarcomas. A retrospective…”
Get full text

Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study by Kurtz, J.E., Kaminsky, M.C., Floquet, A., Veillard, A.S., Kimmig, R., Dorum, A., Elit, L., Buck, M., Petru, E., Reed, N., Scambia, G., Varsellona, N., Brown, C., Pujade-Lauraine, E.

“…CALYPSO (CAeLYx in Platinum Sensitive Ovarian) patients compared carboplatin–pegylated liposomal doxorubicin (C–PLD) with carboplatin–paclitaxel (C–P) in…”
Get full text

Association between recent pregnancy or hormonal contraceptive exposure and outcome of desmoid-type fibromatosis by Debaudringhien, M., Blay, J.-Y., Bimbai, A.-M., Bonvalot, S., Italiano, A., Rousset-Jablonski, C., Corradini, N., Piperno-Neumann, S., Chevreau, C., Kurtz, J.-E., Guillemet, C., Bompas, E., Collard, O., Salas, S., Le Cesne, A., Orbach, D., Thery, J., Le Deley, M.-C., Mir, O., Penel, N.

“…The role of both hormonal contraception and pregnancy on the outcomes of desmoid-type fibromatosis (DF) is debatable. In the present study, we selected female…”
Get full text

Successful treatment of primary cutaneous angiosarcoma of the nose with sequential chemo- and radiotherapy by Herrscher, H., Bronnec, M., Antoni, D., Ghnassia, J.-P., Magnenet, P., Kurtz, J.-E., Noël, G.

“…•The optimal treatment of primary cutaneous angiosarcoma is considered to be surgical exision.•Concurrent chemo-radiotherapy is efficient in the treatment of…”
Get full text

Phase I study of irinotecan and cisplatin in combination with pelvic radiotherapy in the treatment of locally advanced cervical cancer: A GINECO trial by Fabbro, M, Gladieff, L, Guichard, F, El Demery, M, Dalenc, F, Kerr, C, Delannes, M, Paraiso, D, Pujade-Lauraine, E, Kurtz, J.-E

“…Abstract Purpose To define the recommended dose of the association of weekly irinotecan (Iri) and cisplatin (CP) with pelvic radiotherapy in Locally Advanced…”
Get full text

Combined Oral Topotecan plus Carboplatin in Relapsed or Advanced Cervical Cancer: A GINECO Phase I-II Trial by KURTZ, J. E, FREYER, G, PUJADE-LAURAINE, E, JOLY, F, GLADIEFF, L, KAMINSKI, M. C, FABBRO, M, FLOQUET, A, HARDY-BESSARD, A. C, RABAN, N, RAY-COQUARD, I

“…Combined cisplatin-topotecan therapy is standard care for advanced cervical cancer, however it is associated with haematotoxicity and nephrotoxicity. This…”
Get full text

Haematopoietic growth factor in antithyroid‐drug‐induced agranulocytosis by Andrès, E., Kurtz, J.‐E., Perrin, A.‐E., Dufour, P., Schlienger, J.‐L., Maloisel, F.

“…Drug‐induced agranulocytosis (DIA) is often caused by antithyroid drugs. We retrospectively studied the use of granulocyte colony‐stimulating factor (G‐CSF)…”
Get full text

Nonchemotherapy drug-induced agranulocytosis: experience of the Strasbourg teaching hospital (1985-2000) and review of the literature by ANDRÈS, E., KURTZ, J.-E., MALOISEL, F.

“…Agranulocytosis is a life‐threatening disorder that frequently occurs as an adverse reaction to drugs. The overall incidence of nonchemotherapy drug‐induced…”
Get full text

Oral management of patients treated with denosumab for giant cell tumor of bone: A retrospective study at the University Hospitals of Strasbourg by Klienkoff, P., Weingertner, N., Kurtz, J.-E., Bornert, F.

“…Giant cell tumor of bone (GCTB) is defined as a rare intermediate-grade mesenchymal tumor. The first-line treatment was surgery but since the 2010s, denosumab…”
Get full text

Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis by Labidi-Galy, S.I., Rodrigues, M., Sandoval, J.L., Kurtz, J.E., Heitz, F., Mosconi, A.M., Romero, I., Denison, U., Nagao, S., Vergote, I., Parma, G., Nøttrup, T.J., Rouleau, E., Garnier, G., El-Balat, A., Zamagni, C., Martín-Lorente, C., Pujade-Lauraine, E., Fiévet, A., Ray-Coquard, I.L.

“…In the phase III PAOLA-1 study, the addition of maintenance olaparib to bevacizumab in patients with newly diagnosed high-grade ovarian cancer (HGOC) resulted…”
Get full text

Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study by Joly, F., Ahmed-Lecheheb, D., Kalbacher, E., Heutte, N., Clarisse, B., Grellard, J.M., Gernier, F., Berton-Rigaud, D., Tredan, O., Fabbro, M., Savoye, A.M., Kurtz, J.E., Alexandre, J., Follana, P., Delecroix, V., Dohollou, N., Roemer-Becuwe, C., De Rauglaudre, G., Lortholary, A., Prulhiere, K., Lesoin, A., Zannetti, A., N’Guyen, S., Trager-Maury, S., Chauvenet, L., Abadie Lacourtoisie, S., Gompel, A., Lhommé, C., Floquet, A., Pautier, P.

“…Few data are available on long-term fatigue (LTF) and quality of life (QoL) among epithelial ovarian cancer survivors (EOCS). In this case–control study, we…”
Get full text

Precision pain management in interventional radiology by Bauones, S., Cazzato, R.L., Dalili, D., Koch, G., Garnon, J., Gantzer, J., Kurtz, J.E., Gangi, A.

“…Pain is a common manifestation of several benign and malignant conditions. Inadequate response to conservative therapies is often succeeded by incremental use…”
Get full text